Abstract
Cancer cells are distinguished from normal cells by two major characteristics: lack of regulation and limitation in their proliferation. The former is essential and represented as “transformed” with anchorage independency and invasive capabilities, while the latter is not a prerequisite but highly associated and represented as “immortal” concomitant with activation of telomerase. Telomerase is activated in around 80% of human cancers but not in usual somatic cells, and it is responsible for the indefinite proliferation capacity of cancer cells. Therefore, it is natural for physicians to expect telomerase to be useful as a diagnostic and therapeutic target in human cancers. In this chapter, we will overview the characteristics of telomeres and telomerase in human cancers.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787–91.
Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991;196:33–9.
HarleyCB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991;256:271–82.
Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005;26:867–74.
Hastie ND, Dempster M, Dunlop MG, et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990;346:866–8.
de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19:2100–10.
Miyazu YM, Miyazawa T, Hiyama K, et al. Telomerase expression in noncancerous bronchial epithelia is a possible marker of early development of lung cancer. Cancer Res 2005;65:9623–7.
Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer 2007;96:1020–4.
Hiyama E, Hiyama K, Yokoyama T, et al. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249–55.
Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995;87:895–902.
Chumsri S, Matsui W, Burger AM. Therapeutic implications of leukemic stem cell pathways. Clin Cancer Res 2007;13:6549–54.
Cozzio A, Passegue E, Ayton PM, et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003;17:3029–35.
Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464–8.
Ince TA, Richardson AL, Bell GW, et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007;12:160–70.
Sato M, Vaughan MB, Girard L, et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006;66:2116–28.
Ramirez RD, Herbert BS, Vaughan MB, et al. Bypass of telomere-dependent replicative senescence (M1) upon overexpression of Cdk4 in normal human epithelial cells. Oncogene 2003;22:433–44.
Ramirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004;64:9027–34.
Lewis CM, Herbert BS, Bu D, et al. Telomerase immortalization of human mammary epithelial cells derived from a BRCA2 mutation carrier. Breast Cancer Res Treat 2006;99:103–15.
Morales CP, Holt SE, Ouellette M, et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 1999;21:115–18.
Venetsanakos E, Mirza A, Fanton C, et al. Induction of tubulogenesis in telomerase-immor-talized human microvascular endothelial cells by glioblastoma cells. Exp Cell Res 2002;273:21–33.
Hiyama K, Otani K, Ohtaki M, et al. Differentially expressed genes throughout the cellular immortalization processes are quite different between normal human fibroblasts and endothe-lial cells. Int J Oncol 2005;27:87–95.
Olovnikov AM. Principle of marginotomy in template synthesis of polynucleotides (Russian). Dokl Akad Nauk SSSR 1971;201:1496–9.
Watson JD. Origin of concatemeric T7 DNA. Nat New Biol 1972;239:197–201.
Stewart SA, Hahn WC, O'Connor BF, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 2002;99:12606–11.
Chang S, Khoo CM, Naylor ML, et al. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev 2003;17:88–100.
Li S, Rosenberg JE, Donjacour AA, et al. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res 2004;64:4833–40.
Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006;441:1068–74.
Li F, Tiede B, Massague J, et al. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007;17:3–14.
Vermeulen L, Sprick MR, Kemper K, et al. Cancer stem cells — old concepts, new insights. Cell Death Differ 2008;15:947–58.
Zhao YM, Li JY, Lan JP, et al. Cell cycle dependent telomere regulation by telomerase in human bone marrow mesenchymal stem cells. Biochem Biophys Res Commun 2008;369:1114–19.
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–72.
Stadtfeld M, Maherali N, Breault DT, et al. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2008;2:230–40.
Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer 2008;98:677–83.
Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167–79.
Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996;16:53–65.
Kanazawa Y, Ohkawa K, Ueda K, et al. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 1996;225:570–6.
Herbert BS, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005;24:5262–8.
Brunsvig PF, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006;55:1553–64.
Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006;95:1474–82.
Kokhaei P, Palma M, Hansson L, et al. Telomerase (hTERT 611–626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007;35:297–304.
Taki M, Kagawa S, Nishizaki M, et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 (‘Telomelysin-RGD’). Oncogene 2005;24:3130–40.
Agarwal M, Pandita S, Hunt CR, et al. Inhibition of telomerase activity enhances hyperther-mia-mediated radiosensitization. Cancer Res 2008;68:3370–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science + Business Media, LLC
About this chapter
Cite this chapter
Hiyama, K., Hiyama, E., Tanimoto, K., Nishiyama, M. (2009). Role of Telomeres and Telomerase in Cancer. In: Hiyama, K. (eds) Telomeres and Telomerase in Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-60327-879-9_7
Download citation
DOI: https://doi.org/10.1007/978-1-60327-879-9_7
Publisher Name: Humana Press
Print ISBN: 978-1-60327-306-0
Online ISBN: 978-1-60327-879-9
eBook Packages: MedicineMedicine (R0)